Document Detail


Interferon-beta1b for the treatment of multiple sclerosis.
MedLine Citation:
PMID:  18680445     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Multiple sclerosis is a debilitating autoimmune disorder that causes disability in young adults. OBJECTIVE: To review the efficacy and safety of IFN-beta1b in the management of relapsing-remitting and secondary progressive multiple scleroses and clinical isolated syndrome. METHODS: A MEDLINE (1966-May 2007) search of clinical trials using the terms 'multiple sclerosis' and 'interferon' was performed. Manual bibliographic search was conducted. English-language articles were evaluated. RESULTS: IFN-beta1b is more efficacious than placebo and at least as efficacious as IFN-beta1a or glatiramer for the management of relapsing-remitting multiple sclerosis. IFN-beta1b also delayed the time to diagnosis of definite multiple sclerosis and reduced brain lesion burden in patients with clinical isolated syndrome. More long-term, large scale clinical data are warranted to ascertain its relative efficacy compared to other treatments. CONCLUSION: IFN-beta1b is an effective treatment for multiple sclerosis. Common side effects are lymphopenia, injection site reactions, asthenia, flu-like symptoms and headache.
Authors:
Sum Lam; Shan Wang; Malcolm Gottesman
Related Documents :
22425375 - Radial extracorporeal pressure pulse therapy for the primary long bicipital tenosynovit...
22739655 - Vaginoplasty with oxidized cellulose: anatomical, functional and histological evaluation.
22742765 - Clinical and microbiological efficacy of continuous versus intermittent application of ...
22687905 - Analysis of statistical significance for difference of setup error between staff and ne...
24187865 - Curative effect of scraping therapies on lumbar muscle strain.
2025075 - Comparison of postoperative complications between saphenous vein and ima grafts to left...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug metabolism & toxicology     Volume:  4     ISSN:  1742-5255     ISO Abbreviation:  Expert Opin Drug Metab Toxicol     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-08-05     Completed Date:  2008-12-11     Revised Date:  2009-11-16    
Medline Journal Info:
Nlm Unique ID:  101228422     Medline TA:  Expert Opin Drug Metab Toxicol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1111-7     Citation Subset:  IM    
Affiliation:
St. John's University, College of Pharmacy and Allied Health Professions, Department of Clinical Pharmacy Practice, St. Albert's Hall Room 114, 8000 Utopia Parkway, Queens, New York, NY 11439, USA. Lams1@stjohns.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adjuvants, Immunologic / adverse effects,  pharmacology,  therapeutic use*
Clinical Trials as Topic
Humans
Interferon-beta / adverse effects,  pharmacology,  therapeutic use*
Multiple Sclerosis / drug therapy*
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Peptides / therapeutic use
Chemical
Reg. No./Substance:
0/Adjuvants, Immunologic; 0/Peptides; 0/copolymer 1; 145155-23-3/interferon beta-1b; 145258-61-3/interferon beta 1a; 77238-31-4/Interferon-beta

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Insulin glargine and its role in glycaemic management of Type 2 diabetes.
Next Document:  Ambroxol in the 21st century: pharmacological and clinical update.